

Cardium Therapeutics, Inc.  
Form 8-K  
April 11, 2013

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

**pursuant to Section 13 or 15(d) of**  
**the Securities Exchange Act of 1934**

**DATE OF REPORT (Date of earliest event reported): April 5, 2013**

001-33635

(Commission file number)

**CARDIUM THERAPEUTICS, INC.**

(Exact name of registrant as specified in its charter)

Edgar Filing: Cardium Therapeutics, Inc. - Form 8-K

**Delaware**  
(State of incorporation)

**27-0075787**  
(IRS Employer Identification No.)

**12255 El Camino Real, Suite 250**  
**San Diego, California 92130**  
(Address of principal executive offices)

**(858) 436-1000**  
(Registrant's telephone number)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**ITEM 8.01 OTHER EVENTS.**

On April 5, 2013, Cardium Therapeutics, Inc. ( Cardium ) issued a press release presenting highlights of the Company's financial results for fiscal year ended December 31, 2012, and other recent developments. A copy of the press release is attached as Exhibit 99.1 and incorporated by reference herein.

The Company also completed the previously announced initial sale of 2,356 shares of Series A preferred stock of approximately \$2.35 million in gross proceeds under a definitive agreement with a single institutional healthcare fund managed by Sabby Management LLC, Cardium's largest shareholder. The second closing, covering the sale of 1,656 shares of Series A preferred stock, for an additional amount of approximately \$1.65 million in gross proceeds, is contingent upon stockholder approval, which would bring the total financing to approximately \$4.0 million in gross proceeds. Ladenburg Thalmann & Co. Inc., a subsidiary of Ladenburg Thalmann Financial Services Inc., served as the exclusive placement agent on the transaction. The net proceeds from this transaction will be used for general working capital purposes.

**ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.**

(d) Exhibits.

99.1 Press Release of Cardium issued on April 5, 2013

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**CARDIUM THERAPEUTICS, INC.**

Date: April 10, 2013

By: /s/ Christopher J. Reinhard  
**Christopher J. Reinhard**  
**Chief Executive Officer**